Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

Trial Profile

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 May 2016

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders
  • Focus Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 12 May 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 11 Jan 2016 Change in study design as randomized and double blind, primary end points and patient age limit as reported by ClinicalTrials.gov record.
    • 11 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top